Meeting
2018 ASCO Annual Meeting
Hyperacute toxicity with combination ipilimumab (ipi) and anti-PD1 immunotherapy.
Authors
Helen Clare Dearden
Melanoma Institute Australia, Sydney, Australia
Helen Clare Dearden , Lewis Au , Daniel Ying Wang , Lisa Zimmer , Zeynep Eroglu , Jessica Louise Smith , Marcello Curvietto , Chloe Khoo , Victoria Atkinson , Serigne Lo , Alexander Guminski , Georgina V. Long , Shahneen Kaur Sandhu , Paolo Antonio Ascierto , Matteo S. Carlino , Douglas Buckner Johnson , James M. G. Larkin , Alexander M. Menzies
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Citation
J Clin Oncol 36, 2018 (suppl; abstr 9545)
DOI
10.1200/JCO.2018.36.15_suppl.9545
Abstract #
9545
Poster Bd #
372
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
High dose bolus (HDB) interleukin-2 (IL2) and concurrent low dose ipilimumab followed sequentially by nivolumab in patients with advanced melanoma after failure of anti-PD1-based immunotherapy and BRAF-MEK inhibition.
First Author: Ahmad A. Tarhini
Poster
2022 ASCO Annual Meeting
A phase II study to evaluate the safety and efficacy of IMM-101 in combination with checkpoint inhibitors in patients with advanced melanoma: Final results of the IMM-101-015 trial.
First Author: Alberto Fusi
Poster
2021 ASCO Annual Meeting
Patient and treatment characteristics of emergency presentations due to immune-mediated toxicities.
First Author: Sharon Hyo-Eun Nahm
Poster
2020 ASCO Virtual Scientific Program
Combination anti-PD-1 and ipilimumab (ipi) therapy in patients with advanced melanoma and pre-existing autoimmune disorders (AD).
First Author: Lauren Julia Brown